Izard Nobel

Sail Biomedicines is a biotechnology company formed through the 2023 merger of Laronde (originally founded as Izard Nobel) and Senda Biosciences. The company integrates programmable circular RNA (eRNA) technology with advanced nanoparticle delivery systems to create a new class of medicines. Its "Endless RNA" platform is designed to provide stable, long-duration protein expression without the need for repeat dosing associated with traditional mRNA. Sail Biomedicines aims to address a broad spectrum of diseases, including metabolic disorders, oncology, and rare diseases, by leveraging its proprietary design and delivery capabilities. The company's modular approach allows for the rapid design and optimization of therapeutic candidates across multiple indications.